• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PIM 家族在弥漫性大 B 细胞淋巴瘤免疫微环境中的作用及机制。

Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma.

机构信息

Department of Oncology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China.

出版信息

World J Surg Oncol. 2023 Mar 4;21(1):76. doi: 10.1186/s12957-023-02947-5.

DOI:10.1186/s12957-023-02947-5
PMID:36871027
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9985240/
Abstract

BACKGROUND

Diffuse large B cell lymphoma (DLBCL) is a more common non-Hodgkin lymphoma (NHL). This study aims to explore the prognostic value of PIM kinase family in DLBCL and its relationship with the immune microenvironment, to provide a certain reference for the prognosis and treatment of DLBCL.

METHODS

The prognostic value of PIM kinase family in DLBCL from the data set GSE10846 was verified through survival analysis and cox regression analysis. Mutations in PIM kinase family and its relationship with immune cell infiltration were explored with online cBioPortal, TIMER database, and single-gene GSEA analysis. Finally, the expression of PIM kinase family in tissues from DLBCL clinical samples was validated through immunohistochemical staining.

RESULTS

The proteins of PIM kinase family were highly expressed in DLBCL patients, which are good prognostic factors for DLBCL patients. Then, PIM1-3 proteins were positively correlated with the immune infiltration of B cells, whose types of mutations also showed different degrees of correlation with B cells. PIM kinase family proteins also showed a high correlation with PDL1. In addition, PIM kinase family was also associated with the commonly mutated genes in DLBCL, such as MYD88, MYC, and BTK.

CONCLUSION

PIM kinase family may be a potential therapeutic target for DLBCL patients.

摘要

背景

弥漫性大 B 细胞淋巴瘤（DLBCL）是一种较为常见的非霍奇金淋巴瘤（NHL）。本研究旨在探讨 PIM 激酶家族在 DLBCL 中的预后价值及其与免疫微环境的关系，为 DLBCL 的预后和治疗提供一定的参考。

方法

通过生存分析和 COX 回归分析验证了来自数据集 GSE10846 的 PIM 激酶家族在 DLBCL 中的预后价值。通过在线 cBioPortal、TIMER 数据库和单基因 GSEA 分析探索了 PIM 激酶家族的突变及其与免疫细胞浸润的关系。最后，通过免疫组织化学染色验证了 PIM 激酶家族在 DLBCL 临床样本组织中的表达。

结果

PIM 激酶家族的蛋白在 DLBCL 患者中高表达，是 DLBCL 患者的良好预后因素。然后，PIM1-3 蛋白与 B 细胞的免疫浸润呈正相关，其突变类型也与 B 细胞呈不同程度的相关性。PIM 激酶家族蛋白与 PDL1 也呈高度相关性。此外，PIM 激酶家族还与 DLBCL 中常见的突变基因如 MYD88、MYC 和 BTK 相关。

结论

PIM 激酶家族可能是 DLBCL 患者的潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/7eb46b00e58b/12957_2023_2947_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/0ad71003dd1b/12957_2023_2947_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/e48c085ddf68/12957_2023_2947_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/35923bfed795/12957_2023_2947_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/b4513600536a/12957_2023_2947_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/b75f1652ce36/12957_2023_2947_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/9dd1ac02aab6/12957_2023_2947_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/7eb46b00e58b/12957_2023_2947_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/0ad71003dd1b/12957_2023_2947_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/e48c085ddf68/12957_2023_2947_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/35923bfed795/12957_2023_2947_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/b4513600536a/12957_2023_2947_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/b75f1652ce36/12957_2023_2947_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/9dd1ac02aab6/12957_2023_2947_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e954/9985240/7eb46b00e58b/12957_2023_2947_Fig7_HTML.jpg

相似文献

1
Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma.PIM 家族在弥漫性大 B 细胞淋巴瘤免疫微环境中的作用及机制。
World J Surg Oncol. 2023 Mar 4;21(1):76. doi: 10.1186/s12957-023-02947-5.
2
CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironment.CCL8 在弥漫性大 B 细胞淋巴瘤 M2 巨噬细胞相互作用中作为一个有前途的预后因素：肿瘤微环境的生物信息学分析。
Front Immunol. 2022 Aug 22;13:950213. doi: 10.3389/fimmu.2022.950213. eCollection 2022.
3
PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.PIM 激酶是弥漫性大 B 细胞淋巴瘤的进展标志物和新兴治疗靶点。
Br J Cancer. 2012 Jul 24;107(3):491-500. doi: 10.1038/bjc.2012.272. Epub 2012 Jun 21.
4
Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.在弥漫性大 B 细胞淋巴瘤中抑制 PIM 激酶可靶向 MYC 转录程序，并增强抗 CD20 抗体的疗效。
Cancer Res. 2021 Dec 1;81(23):6029-6043. doi: 10.1158/0008-5472.CAN-21-1023. Epub 2021 Oct 8.
5
Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.PIM2缺失增强了泛PIM激酶抑制剂AZD1208在非霍奇金淋巴瘤中的抗增殖作用。
Mol Cancer. 2015 Dec 8;14:205. doi: 10.1186/s12943-015-0477-z.
6
Significance of chromobox protein (CBX) expression in diffuse LBCL.弥漫性大 B 细胞淋巴瘤中 chromobox 蛋白（CBX）表达的意义。
Gene. 2022 Mar 1;813:146092. doi: 10.1016/j.gene.2021.146092. Epub 2021 Dec 9.
7
Evaluation of a five-gene signature associated with stromal infiltration for diffuse large B-cell lymphoma.评估与弥漫性大B细胞淋巴瘤基质浸润相关的五基因特征。
World J Clin Cases. 2021 Jun 26;9(18):4585-4598. doi: 10.12998/wjcc.v9.i18.4585.
8
Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.原发性中枢神经系统弥漫性大 B 细胞淋巴瘤的肿瘤微环境和免疫检查点特征。
Virchows Arch. 2020 Jun;476(6):891-902. doi: 10.1007/s00428-019-02695-6. Epub 2019 Dec 6.
9
Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.基于代谢相关基因特征鉴定弥漫性大 B 细胞淋巴瘤的分子亚型和新的预后模型。
J Transl Med. 2022 Apr 25;20(1):186. doi: 10.1186/s12967-022-03393-9.
10
Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.PIM激酶对活化B细胞弥漫性大B细胞淋巴瘤中翻译激活的调控赋予了对PIM447抑制的敏感性。
Oncotarget. 2016 Sep 27;7(39):63362-63373. doi: 10.18632/oncotarget.11457.

引用本文的文献

1
PIM3 Kinase: A Promising Novel Target in Solid Cancers.PIM3激酶：实体癌中一个有前景的新型靶点。
Cancers (Basel). 2024 Jan 26;16(3):535. doi: 10.3390/cancers16030535.
2
Identifying as a potential biomarker by the comprehensive exploration of tumor mutational burden and immune infiltration in diffuse large B cell lymphoma.通过全面探索肿瘤突变负担和弥漫性大 B 细胞淋巴瘤中的免疫浸润来鉴定为潜在的生物标志物。
PeerJ. 2023 Dec 11;11:e16618. doi: 10.7717/peerj.16618. eCollection 2023.

本文引用的文献

1
PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma.PIM2 激酶在浆母细胞生成和浆细胞存活中发挥关键作用，为骨髓瘤开辟了新的治疗选择。
Blood. 2022 Apr 14;139(15):2316-2337. doi: 10.1182/blood.2021014011.
2
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.伊布替尼联合 R-CHOP 化疗治疗弥漫性大 B 细胞淋巴瘤的遗传学亚型。
Cancer Cell. 2021 Dec 13;39(12):1643-1653.e3. doi: 10.1016/j.ccell.2021.10.006. Epub 2021 Nov 4.
3
Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
在弥漫性大 B 细胞淋巴瘤中抑制 PIM 激酶可靶向 MYC 转录程序，并增强抗 CD20 抗体的疗效。
Cancer Res. 2021 Dec 1;81(23):6029-6043. doi: 10.1158/0008-5472.CAN-21-1023. Epub 2021 Oct 8.
4
Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects.癌症治疗中 PIM 激酶信号的治疗靶向：结构和临床前景。
Biochim Biophys Acta Gen Subj. 2021 Nov;1865(11):129995. doi: 10.1016/j.bbagen.2021.129995. Epub 2021 Aug 26.
5
assessment of the efficiency of the PIM-1 kinase pharmacological inhibitor as a potential treatment for Burkitt's lymphoma.评估PIM-1激酶药理抑制剂作为伯基特淋巴瘤潜在治疗方法的有效性。
Oncol Lett. 2021 Aug;22(2):622. doi: 10.3892/ol.2021.12883. Epub 2021 Jun 29.
6
Expression and ERG regulation of PIM kinases in prostate cancer.前列腺癌中 PIM 激酶的表达和 ERG 调节。
Cancer Med. 2021 May;10(10):3427-3436. doi: 10.1002/cam4.3893. Epub 2021 May 1.
7
Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis.长链非编码 RNA LINC01003 通过靶向 miR-33a-5p/PIM1 轴抑制多发性骨髓瘤的发展。
Leuk Res. 2021 Jul;106:106565. doi: 10.1016/j.leukres.2021.106565. Epub 2021 Mar 31.
8
Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics.蛋白激酶PIM2：一种在癌症代谢和治疗中具有复杂功能的简单PIM家族激酶。
J Cancer. 2021 Mar 5;12(9):2570-2581. doi: 10.7150/jca.53134. eCollection 2021.
9
Androgen Receptor and Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer.雄激素受体和表达在三阴性乳腺癌患者的肿瘤组织中。
Cancer Genomics Proteomics. 2021 Mar-Apr;18(2):147-156. doi: 10.21873/cgp.20249.
10
PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF-κB Activity.PIM 激酶通过调节 JAK-STAT 和 NF-κB 活性促进原发性纵隔大 B 细胞淋巴瘤的存活和免疫逃逸。
Am J Pathol. 2021 Mar;191(3):567-574. doi: 10.1016/j.ajpath.2020.12.001. Epub 2020 Dec 8.